Current Report Filing (8-k)
October 06 2017 - 7:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event Reported): October 5, 2017
Curis, Inc.
(Exact Name
of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
000-30347
|
|
04-3505116
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Number)
|
4 Maguire Road, Lexington, MA 02421
(Address of Principal Executive Offices) (Zip Code)
(617)
503-6500
(Registrants telephone number, including area code)
Not Applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of
this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers.
|
(b)
On October 5, 2017, Kenneth J. Pienta, M.D. notified the Board of Directors of Curis, Inc. (the Company), that, effective immediately, he will resign as a member of the Board of Directors to pursue other opportunities, including in
the biotechnology industry. The Board and the management team join together in thanking Dr. Pienta for his services as a member of the Board of Directors, and wish him well in all of his endeavors.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Curis, Inc.
|
|
|
|
|
Date: October 6, 2017
|
|
|
|
By:
|
|
/s/ Ali Fattaey, Ph.D.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ali Fattaey, Ph.D.
|
|
|
|
|
|
|
President and Chief Executive Officer
|
Curis (NASDAQ:CRIS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Curis (NASDAQ:CRIS)
Historical Stock Chart
From Apr 2023 to Apr 2024